GSK raises long-term profit outlook amid vaccine boost
by Holly Williams
Jan 31, 2024
2 minutes
Drugs giant GSK has upgraded its long-term profit outlook after unveiling higher annual sales and profits thanks to the launch of a new blockbuster vaccine.
The group posted a 14% increase in pre-tax profits on a constant currency basis to £6.1 billion for 2023 after sales
You’re reading a preview, subscribe to read more.
Start your free 30 days